Results 91 to 100 of about 88,087 (318)

Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review

Pharmaceutics, 2020
Clinical research in high-income countries is increasingly demonstrating the cost- effectiveness of clinical pharmacogenetic (PGx) testing in reducing the incidence of adverse drug reactions and improving overall patient care.
Emiliene B Tata, Melvin A Ambele, Michael S Pepper   +2 more
semanticscholar   +1 more source

Rules of Thumb for Estimating Drug Levels in Breast Milk: How Well Do They Work?

Clinical Pharmacology &Therapeutics, EarlyView.
The American Academy of Pediatrics and the World Health Organization recommend exclusive breastfeeding for the first 6 months of life due to extensive benefits for the maternal–infant dyad. While over 90% of mothers initiate breastfeeding, continuation drops to 35% by 6 months, often due to concerns about medication safety.
Juliya Gasparyan, Philip O. Anderson, Tamorah Lewis, Cindy H. T. Yeung   +3 more
wiley   +1 more source

CLOPIDOGREL PHARMACOGENETICS

Рациональная фармакотерапия в кардиологии, 2016
Platelets play an important role in the pathogenesis of atherosclerosis. They are involved in atherosclerosis progression and thrombotic complications. That is why antiplatelet therapy is a necessary element of these complications prevention in patients ...
A. N. Meshkov
doaj   +1 more source

Association of Atypical Antipsychotics With Lipid Abnormalities in Adult Patients With Schizophrenia: A Scoping Review. [PDF]

Neuropsychopharmacol Rep
This scoping review highlights the link between atypical antipsychotics and dyslipidaemia in adults with schizophrenia, identifying clozapine and olanzapine as high‐risk agents. Biomarkers and genetic polymorphisms offer promise for personalized treatment. Further research is needed on lesser‐studied drugs and predictive tools.
Abavana V, Sadiq S.
europepmc   +2 more sources

Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. [PDF]

, 2014
Hypertension after treatment with vascular endothelial growth factor (VEGF) receptor inhibitors is associated with superior treatment outcomes for advanced cancer patients.
Bakris, GL, Cohen, EEW, Fleming, GF, House, LK, Karovic, S, Karrison, TG, Levine, MR, Maitland, ML, Ratain, MJ, Rudek, MA, Thomeas, V, Wen, Y, Wright, JJ, Wu, K   +13 more
core   +2 more sources

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

Expert Opinion on Drug Metabolism & Toxicology, 2018
Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some patients do not respond adequately or develop treatment related adverse events. This
Nihal El Rouby, J. Lima, Julie A. Johnson   +2 more
semanticscholar   +1 more source

Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomics implementation efforts have increased over the last decade, but no published prospective pharmacogenomics trials have formally evaluated utility in underrepresented populations. We present final results from the ACCOuNT trial, a multi‐institutional prospective study [NCT03225820] in which African American inpatients were genotyped and ...
Zhong Huang, Kevin J. O'Leary, Edith A. Nutescu, Matthew Jack, Thomas Chen, Gregory W. Ruhnke, James C. Lee, David George, Larry K. House, Randall Knoebel, Luke V. Rasmussen, Seth Hartman, Anish Choksi, Kiang‐Teck J. Yeo, Minoli A. Perera, Mark J. Ratain, David O. Meltzer, Peter H. O'Donnell   +17 more
wiley   +1 more source

Evaluation of Characteristics and Ethnic Sensitivity for FDA-Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy. [PDF]

J Clin Pharmacol
Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Fukuhara K, Tanetsugu Y, Wada S, Muto C, Kawai N.   +4 more
europepmc   +2 more sources

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine

Diabetes/Metabolism Research Reviews, 2019
Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control, it is often necessary to rely on combination therapy of multiple drugs or insulin because uncontrolled ...
G. Mannino, F. Andreozzi, G. Sesti
semanticscholar   +1 more source

Pharmacogenetics of schizophrenia

Expert Opinion on Pharmacotherapy, 2006
There is substantial unexplained interindividual variability in the drug treatment of schizophrenia. A substantial proportion of patients respond inadequately to antipsychotic drugs, and many experience limiting side effects. As genetic factors are likely to contribute to this variability, the pharmacogenetics of schizophrenia has attracted substantial
Reynolds, Gavin, Templeman, L.A., Godlewska, B.R.   +2 more
openaire   +4 more sources